A5052243751- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Nutrition and Health in Aging
- Colorectal Cancer Surgical Treatments
- Lung Cancer Research Studies
- Bioactive Compounds and Antitumor Agents
- Lung Cancer Treatments and Mutations
- Morinda citrifolia extract uses
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Screening and Detection
- Skin Protection and Aging
- Cancer Research and Treatments
- Economic and Financial Impacts of Cancer
- Peptidase Inhibition and Analysis
- Dysphagia Assessment and Management
- Cancer survivorship and care
- BRCA gene mutations in cancer
- Oral health in cancer treatment
University of Alberta
2004-2024
Alberta Cancer Foundation
2024
CancerCare Manitoba
2007-2023
Memorial Sloan Kettering Cancer Center
2007-2023
Marqués de Valdecilla University Hospital
2008-2023
Canadian Red Cross Society
2020
Flinders Medical Centre
2012
Flinders University
2012
AstraZeneca (Italy)
2012
Princess Margaret Cancer Centre
2009
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
Body composition has emerged as an important prognostic factor in cancer patients. Severe depletion of skeletal muscle (sarcopenia) and, hence, overall lean body mass may represent occult condition individuals with normal or even high weight. Sarcopenia been associated poor performance status, 5-fluorouracil toxicity, and shortened survival Here, we prospectively studied patients metastatic breast receiving capecitabine treatment order to determine if sarcopenia was a higher incidence...
Purpose To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC). Patients Methods The initial design of this trial was a randomized, two-arm, noninferiority, phase III comparison XELOX versus FOLFOX-4. After patient accrual had begun, the amended 2003 after bevacizumab data became available. resulting 2 × factorial randomly assigned patients FOLFOX-4, then also receive...
<h3>Importance</h3> Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than those patients who are microsatellite-instability high (MSI-H). <h3>Objective</h3> To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) improved patient survival metastatic CRC. <h3>Design, Setting, Participants</h3> A randomized phase 2 study was conducted 27 centers across Canada...
To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC).
We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid (FOLFOX4) as first-line therapy in metastatic colorectal cancer. NO16966 was a randomised, two-arm, non-inferiority, phase III comparison of XELOX FOLFOX4, subsequently amended to 2 × factorial design with further randomisation bevacizumab or placebo. A planned follow-up exploratory analysis OS performed. The intent-to-treat (ITT) population...
To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that bevacizumab (anti-VEGF-A monoclonal antibody) in combination chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC).HORIZON III [Cediranib Plus FOLFOX6 Versus Bevacizumab Patients With Untreated Metastatic Colorectal Cancer] had an adaptive phase II/III design. randomly assigned 1:1:1 received mFOLFOX6 [oxaliplatin 85 mg/m(2) and...
Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other medications though, it may suffer from drug interactions that could impair its absorption.To determine if gastric acid suppressants such as proton pump inhibitors (PPIs) capecitabine efficacy.This secondary analysis of TRIO-013, a phase III randomized trial, compares and oxaliplatin (CapeOx) or without lapatinib in 545 patients ERBB2/HER2-positive metastatic gastroesophageal (GEC); were 1:1...
Importance Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair–proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by presence liver metastases (LM). Objective To investigate association between LM and ICI advanced MSS Design, Setting, Participants In this secondary analysis Canadian Cancer Trials Group CO26 (CCTG CO.26) randomized clinical trial, patients with treatment-refractory cancer...
4028 Background: NO16966 is the first phase III trial to evaluate combination of Bev with oxaliplatin-based chemotherapy (FOLFOX4 or XELOX regimen) in first-line setting. Methods: 1401 pts were randomized receive FOLFOX4 (oxaliplatin, 5-FU, leucovorin as described previously) (oxaliplatin 130mg/m 2 iv, capecitabine 1000mg/m bid oral d1–14, q3w) plus (5mg/kg q weeks for FOLFOX, 7.5mg/kg 3 XELOX) Placebo a 2x2 factorial design. Results: The addition demonstrated significant benefit terms PFS...
National Cancer Institute of Canada Clinical Trials Group CO.17 demonstrated the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and progression-free survival in patients with advanced, chemotherapy-refractory colorectal cancer (CRC), particularly wild-type KRAS tumors. This article reports health-related quality-of-life (HRQL) outcomes from CO.17.Patients (N = 572) pretreated EGFR-detectable advanced CRC were randomly assigned to best...
We aimed to determine the effects of systemic inflammation and symptoms head neck cancer patients on dietary intake weight in relation mode treatment.In all, 38 orally fed had intake, weight, C-reactive protein (CRP), prospectively assessed at baseline, post-treatment, follow-up.Intake/weight declined CRP increased substantially chemoirradiation (-11.4 ± 5.2 kg, -1214 kcal/day, 23.4 24.9 mg/L; p < .05) versus radiotherapy (-3.5 4.8 -483 8.3 13.9 mg/L) during posttreatment (repeated-measures...
4030 Background: In a phase II study in untreated MCRC patients, XELOX (capecitabine + oxaliplatin) appeared to have similar efficacy compared with previously published FOLFOX4 data [1]. We therefore started III 2-arm open-label non-inferiority comparing FOLFOX4. 2003 the addition of bevacizumab (Bev) irinotecan/5-FU/LV was shown improve progression-free survival (PFS) and overall [2]. then amended our trial 2x2 partially blinded assess Bev. Methods: Original study: (oxaliplatin 130 mg/m 2...
481 Background: D is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor. T mAb against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Targeting both PD-L1 and CTLA-4 may have additive/synergistic activity as mechanisms action inhibition are non-redundant. This study evaluated whether combining would lead improved pt survival vs BSC alone in rCRC. Methods: Pts with rCRC were randomized 2:1 D+T . eligible if they failed...
•Patients were able to increase and sustain dietary protein intake from preintervention levels.•Over one-half of patients in the 2.0 g/kg/day group maintained or gained MM with a 12-week targeted nutrition intervention.•This work highlighted potential for attenuate loss cancer. BackgroundLow muscle mass (MM) predicts unfavorable outcomes Protein supports health, but oncologic recommendations are not well characterized. The objectives this study evaluate feasibility change attain 1.0 diets,...
Monoclonal antibodies against the epidermal growth factor receptor (anti-egfr) when used in treatment of metastatic colorectal cancer are associated with improved survival. Patients whose tumours harbor a KRAS mutation codon 12 or 13 have been shown not to benefit from anti-egfr antibodies. The importance status management patients has led elaboration Canadian consensus recommendations on testing, aim standardizing practice across Canada and reconciling testing access clinical demand for...
3512 Background: Targeting both PD-L1 and CTLA-4 may be synergistic immunotherapy approaches. CO.26 evaluated if dual inhibition leads to improved pt survival vs BSC alone in rmCRC. Methods: rmCRC pts were randomized 2:1 D+T BSC. Treatment consisted of D (1500 mg) D1 q 28 days T (75 for first 4 cycles, supportive measures. Primary endpoint was overall (OS). Two-sided p < 0.10 considered statistically significant. Cell-free (cf)DNA sequencing MSI TMB used GuardantOMNI panel baseline...